A new verdict for an old convict.
Certain human cancers and carcinogen-induced rodent tumors commonly contain Kras2 mutations. This activated form of ras has always been described as a dominant oncogene. A new study indicates that wildtype Kras2 has properties of a tumor suppressor gene and may have the capacity to reduce the transforming potential of oncogenically activated ras.
Pfeifer
G P
GP
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins